Advertisement
Table 1 Characteristics of patients with unfavorable cancer of unknown primary site (n = 179)
| Characteristic | No. of patients | % |
|---|---|---|
| Median age at diagnosis, year (range, IQR) | 73 (30-98, 58-80) | |
| Gender | ||
| Male | 128 | 71.5 |
| Female | 51 | 28.5 |
| Histology | ||
| Carcinoma, unclassifiable | 83 | 46.4 |
| Adenocarcinoma | 71 | 39.7 |
| Squamous cell carcinoma | 6 | 3.4 |
| Neuroendocrine carcinoma | 12 | 6.7 |
| Others | 7 | 3.9 |
| Histologic grade | ||
| Poorly differentiated or Undifferentiated | 31 | 17.3 |
| Unspecified | 148 | 82.7 |
| Performance status | ||
| 0 | 19 | 10.6 |
| 1 | 67 | 37.4 |
| 2 | 44 | 24.6 |
| 3 | 27 | 15.1 |
| 4 | 22 | 12.3 |
| Initial site at diagnosis | ||
| Liver | 38 | 21.2 |
| Lung | 23 | 12.8 |
| Bone | 47 | 26.3 |
| Central nervous system | 7 | 3.9 |
| Peritoneum | 18 | 10.1 |
| Lymph nodes | 43 | 24 |
| Others | 3 | 1.7 |
| Sites of disease involvement | ||
| Liver | 80 | 44.7 |
| Lung and pleural | 87 | 48.6 |
| Bone | 74 | 41.3 |
| Central nervous system | 14 | 7.8 |
| Lymph nodes | 107 | 59.8 |
| No. of metastatic organs | ||
| 1 | 40 | 22.3 |
| 2 | 52 | 29.1 |
| > 2 | 87 | 48.6 |
| Treatment | ||
| Chemotherapy | 118 | 66.0 |
| Radiotherapy | 52 | 29.1 |
| Tyrosine kinase inhibitors | 2 | 1.1 |
| Chemotherapy regimens | ||
| Cisplatin-based | 89 | 75.4 |
| 5-FU-based | 51 | 43.2 |
| Etoposide-based | 45 | 38.1 |
| Gemcitabine-based | 17 | 14.4 |
| Taxane-based | 13 | 11.0 |
| Oxaliplatin-based | 11 | 9.3 |
